Can acetylcysteine ameliorate cisplatin‐induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double‐blind, placebo‐controlled trial involving patients with head and neck cancer
Authors:
Open Access
- 11 April 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (5) , 2020-2030
Abstract
The protective antioxidant activity of acetylcysteine (NAC) against toxicity due to cisplatin has been reported in experimental models; however, its efficacy in patients has not been elucidated. The aim of this study was to investigate the possible protective effect of NAC on cisplatin‐induced toxicity and the effect of NAC on clinical response and oxidative stress in patients treated for head and neck cancer. This was a randomized, double‐blind, placebo‐controlled trial conducted in patients receiving high‐dose cisplatin chemotherapy concomitant to radiotherapy. Patients were randomly assigned to groups and received: (a) 600 mg NAC syrup, orally once daily at night for 7 consecutive days or (b) placebo, administered similarly to NAC. Nephro‐, oto‐, hepato‐, myelo‐, and gastrointestinal toxicities, clinical responses, and plasma and cellular markers of oxidative stress were evaluated. Fifty‐seven patients were included (n = 28, NAC arm; and n = 29, placebo arm). A high prevalence of most types of toxicities was observed after cisplatin chemotherapy; however, the parameters were similar between the two groups. There was a predominance of partial response to treatment. In the cellular and plasmatic oxidative stress analyses, minor differences were observed. Overall, there was no statistically significant difference between the groups for all outcomes. These findings show that low‐dose oral NAC does not protect patients with head and neck cancer from cisplatin‐induced toxicities and oxidative stress. The antitumor efficacy of cisplatin was apparently not impaired by NAC.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/04744‐7, 2014/18294‐3, 2015/01793‐0, 17/17728‐8)
This publication has 43 references indexed in Scilit:
- Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic FunctionsPLOS ONE, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Multicenter Approach to Recurrent Acute and Chronic Pancreatitis in the United States: The North American Pancreatitis Study 2 (NAPS2)Pancreatology, 2008
- Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat modelsCancer Chemotherapy and Pharmacology, 2007
- Protective effect of cyclic AMP against cisplatin-induced nephrotoxicityFree Radical Biology and Medicine, 2006
- d-Methionine attenuated cisplatin-induced vestibulotoxicity through altering ATPase activities and oxidative stress in guinea pigsToxicology and Applied Pharmacology, 2006
- The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling PathwayThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled studyEuropean Journal of Cancer, 2004
- Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteineEuropean Journal of Clinical Pharmacology, 1988
- Bronchogenic carcinoma in Northern India.Thorax, 1982